Proven protection from sudden cardiac death and so much more - 1 in 14 patients require arrhythmia intervention while wearing the LifeVest

Case Studies

LifeVest Network Homepage »

Learn how the LifeVest® wearable cardioverter defibrillator (WCD) captured arrhythmic events that enabled physicians to modify the treatment path for their patients. 

Atrial Fibrillation Case StudyAtrial Fibrillation

Newly diagnosed heart failure patient with an EF of 20%. Atrial fibrillation events recorded by LifeVest altered the course of treatment for the patient.

Read more »

Bradycardia Case StudyBradycardia

NSTEMI patient with an EF of 30%. Bradycardia events recorded by LifeVest revealed significant underlying cardiovascular disease.

Read more »

 

Sinus Tachycardia Case StudySinus Tachycardia

STEMI patient post-PCI with an EF of 29%. Sinus tachycardia events recorded by LifeVest altered the course of treatment for the patient.

Read more »

Sustained VT Case StudySustained VT

Dilated cardiomyopathy patient with an EF of ≤ 35%. A ventricular tachycardia event recorded by LifeVest altered the course of treatment for the patient.

Read more »

 

Syncope Case StudySyncope

STEMI patient with an EF of 30%. Data recorded by LifeVest revealed recurring bradycardia events that required pacemaker implantation.

Read more »

Trends Case StudyTrends

Non-ischemic cardiomyopathy patient with an EF of 20%. Data collected from LifeVest altered the course of treatment for the patient.

Read more »

 

LifeVest Network Homepage »

Proven protection from Sudden Cardiac Death1,2 + so much more™
1 in 14 patients diagnosed with an arrhythmia requiring intervention while wearing the LifeVest.3
With the LifeVest Network, you can capture arrhythmic events including: Sustained VT, Non-Sustained VT, Atrial Arrhythmias/SVT,* Severe Bradycardia/Asystole.

1 Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol. 2010;56(3):194–203.
2 Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post myocardial infarction.
3 Kutyifa V. Goldenberg I, Zareba W, et al. Results from the prospective registry of patients using the wearable defibrillator (WEARIT-II registry). Presented as late breaking clinical trial at the 2014 European Society of Cardiology Congress, Sept 3, 2014.
*When the rhythm meets heart rate and morphology criteria, or through a patient initiated recording.